Saturday, July 11, 2026

Drug profile · INN

efungumab

efungumab (MYCOGRAB) is a heat shock protein 90 homolog inhibitor.

EMA: refused Antiinfectives for systemic use (J02) J02
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — efungumab
Class
Antiinfectives for systemic use (J02)
Route
Patents
0
Programs
1
Data quality
0.83

Quick answer

efungumab (MYCOGRAB) is a heat shock protein 90 homolog inhibitor.

Key facts

INN efungumab
Brand MYCOGRAB
Mechanism Heat shock protein 90 homolog inhibitor
Target Heat shock protein 90 homolog
Therapeutic class Antiinfectives for systemic use (J02)
ATC code J02

Mechanism of action

Heat shock protein 90 homolog inhibitor

Primary target: Heat shock protein 90 homolog

Approval history

Authority Status Date
EMA refused

Pipeline programs

  1. Gum chewing Phase 3 · Chia Tai Tianqing · Recovery of Bowel Function, Due to Gum Chewing

Related & competitor drugs

  1. atazanavir sulfate Antiinfectives for systemic use (J05)
  2. colistimethate sodium Antiinfectives for systemic use (J01)
  3. covid-19 mrna vaccine Antiinfectives for systemic use (J07)
  4. daptomycin Antiinfectives for systemic use (J01)
  5. darunavir Antiinfectives for systemic use (J05)
  6. dengue tetravalent vaccine (live, attenuated) Antiinfectives for systemic use (J07)

Frequently asked questions

What is efungumab?

efungumab (MYCOGRAB) is a heat shock protein 90 homolog inhibitor.

What is the brand name for efungumab?

MYCOGRAB is a marketed brand name for efungumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.